Skip to main content
. 2020 Nov 12;10:19733. doi: 10.1038/s41598-020-76751-6

Table 5.

Physicochemical properties and biological responses of the NLC formulations developed for articaine.

Physicochemical properties Biological responses
Formulation Size (nm) PDI ZP (mV) %EE Anti-inflammatory property Bradycardia (bpm ± SD)a Bradycardia-recovery time (h)b Anesthesia improvement (% ± SD) c
NLC-CP1-A 237.0 ± 0.4 0.167 ± 0.001 − 38.3 ± 0.5 74.8 ± 1.2 No 68 ± 4 2 58 ± 6
NLC-CP2-A 237.6 ± 3.3 0.169 ± 0.015 − 42.1 ± 0.5 66.8 ± 2.3 No 60 ± 6 2 50 ± 0
NLC-CO1-A 256.4 ± 0.2 0.200 ± 0.009 − 43.7 ± 0.6 70.5 ± 1.4 Yes 18 ± 3 3 100 ± 0
NLC-CO2-A 217.7 ± 0.8 0.174 ± 0.004 − 40.2 ± 1.1 70.6 ± 1.8 Yes 25 ± 4 3 100 ± 4
NLC-OO1-A 254.1 ± 1.8 0.190 ± 0.005 − 42.2 ± 0.5 68.3 ± 1.9 Yes 50 ± 3 2 54 ± 6
NLC-OO1-A 243.3 ± 5.8  ± 0.176 ± 0.022 − 49.7 ± 0.7 68.0 ± 2.5 Yes 47 ± 3 2 54 ± 6

Size = nanoparticle diameter, in nm; PDI polydispersity index, ZP zeta potential, in mV, %EE percent encapsulation efficiency of articaine, bpm heart beats per minute.

aWith 1 mM ATC, after 1 hpi; bwith 1 mM ATC; cformulations containing 0.5 mM ATC, in relation to free ATC at the same concentration.